Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya

Is operational research delivering the goods? The journey to success in low-income countries

“…Importantly, NGO advocacy can exert eff ective pressure on policy makers to act on the evidence quickly. 15,[58][59][60] Health outcomes are often dependent on communitybased support systems, particularly for diseases such as tuberculosis and HIV. Thus, engaging with communities, including civil society organisations, 61 and where possible establishing community advisory boards to provide a link between researchers and the community, will probably help with research implementation as well as adoption of the results.…”

“…11 Similar examples of engagement of stakeholders at the outset of research include a study showing the benefi ts of co-trimoxazole prophylaxis for people with HIV and another noting the negative eff ect of user fees on patients' outcomes in HIV programmes. [15][16][17] The key message from these experiences is that, at the outset, the most important people needed to support and implement the study fi ndings should be identifi ed and engaged.…”

Barriers to Antiretroviral Treatment in Ethiopia: A Qualitative Study

“…If the HIV-positive status is not disclosed, patients my compromise their adherence to ARV medications by taking their medicines secretly and irregularly, they may skip their daily doses if privacy is unavailable at a scheduled dosing time or decide to boycott treatment. [6][7][8][9] Health-system level barriers such as long walking distance between home and care providing health facilities, lack of coordination of services within health facilities, and limited involvements of the community in the planning process are hindering factors of good ART adherence in many settings. [3][4][5] Out-of-pocket expenses such as user fees for registration and laboratory tests, and cost of long-distance transportation remain important barriers to sustain adherence and medical care.…”

“…Missed work-hours during regular clinical follow-up is additional economic burden to PLHIVs in care and treatment and their families. [4][5][6][7][8] In low-income countries, longer waiting time in ART clinic is a daunting challenge that has contributed to poor adherence to ARV medications and attrition from treatment. 7 Inadequate expansion of ART services, shortage of health workforce particularly ART-trained cadres and dilapidated infrastructure like rooms and laboratory facilities combined with huge HIVpositive population in some resource-limited settings contributed to long waiting time in ART clinics.…”

Les financements de la prise en charge du VIH/SIDA dans les pays en développement : le cas de l’Afrique Sub-saharienne

“…Malgré les efforts considérables engagés par les acteurs nationaux et internationaux de la lutte contre le VIH/SIDA dans les pays à ressources limitées, l'accès à la prise en charge des personnes vivant avec le VIH/SIDA demeure un problème de santé publique majeur 5,6 . Dans la plupart de ces pays, le financement de la prise en charge du VIH/SIDA repose essentiellement sur la contribution financière des ménages 7 . Ces derniers participent, généralement, pour plus de 50 % au financement global de la prise en charge, faisant ainsi face à des dépenses de santé désastreuses 8 .…”